Ischemic acute tubular necrosis models and drug discovery: a focus on cellular inflammation

• Published in: Drug discovery today Vol. 11; no. 7; pp. 364 - 370
• Main Authors: Ikeda, Masahiro, Prachasilchai, Worapat, Burne-Taney, Melissa J., Rabb, Hamid, Yokota-Ikeda, Naoko
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.04.2006; Elsevier Science
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; B-Lymphocytes - drug effects; B-Lymphocytes - metabolism; Biological and medical sciences; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical - methods; Gene Expression Profiling; Gene Expression Regulation; General pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Inflammation - drug therapy; Inflammation - metabolism; Ischemia - drug therapy; Ischemia - genetics; Ischemia - metabolism; Kidney - blood supply; Kidney Tubular Necrosis, Acute - drug therapy; Kidney Tubular Necrosis, Acute - genetics; Kidney Tubular Necrosis, Acute - metabolism; Medical sciences; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - pharmacology; Mycophenolic Acid - therapeutic use; Oligonucleotide Array Sequence Analysis; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; T-Lymphocytes - drug effects; T-Lymphocytes - metabolism; Drug; Acute tubular necrosis; Pharmaceutical technology; Ischemia; Pathophysiology; Cardiovascular disease; Inflammation; Models; In vitro; Research and development
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2006.02.010

Acute renal failure (ARF) is a common cause of mortality and morbidity in hospitalized patients. Ischemia is an important cause of ARF, and ARF caused by ischemic injury is referred to as ischemic acute tubular necrosis (ATN). There is growing evidence from models that ischemic ATN is associated with intrarenal inflammation. Consequently, intrarenal inflammation is an attractive target for the development of novel drug therapies for ARF. This review outlines ischemic ATN models, the pathophysiogical roles of inflammatory cells such as T and B cells in ischemic ATN models, and effective T and B cell therapeutic reagents.